帕金森病不同疾病阶段的神经影像生物标志物综述
本综述系统梳理了帕金森病临床前、前驱期、早期和中晚期可用的影像生物标志物,涵盖磁共振扩散成像、神经黑色素敏感成像、铁敏感成像、T1加权成像及多巴胺能、5-羟色胺能、胆碱能PET/SPECT和代谢/脑血流网络成像。文章强调疾病状态标志物在各阶段相对稳定,而进展标志物的可靠性随疾病阶段变化,为临床试验和临床管理中选择合适的影像终点提供了分阶段框架。
要点
- 临床前和前驱期可选用纹状体多巴胺能成像、代谢成像及黑质自由水/神经黑色素/铁敏感成像作为疾病状态标志物。
- 早期帕金森病进展可用纹状体多巴胺能成像、代谢成像及后部黑质自由水和神经黑色素敏感成像监测。
- 中晚期进展可用前部黑质自由水成像、黑质R2*和代谢成像监测,多巴胺能成像和自由水成像可检测1年进展。
核心结论
- 帕金森病各阶段均有可用的影像生物标志物作为临床试验结局指标,并可多模态结合常规临床评估使用。
- 实施诊断和进展生物标志物时需考虑疾病阶段,本综述为此提供了分阶段框架。
研究设计与样本
- 综述纳入帕金森病临床前、前驱期、早期和中晚期各阶段的磁共振成像、PET/SPECT分子成像及代谢和脑血流网络成像生物标志物。
主要发现
- 临床前和前驱期潜在可用的疾病状态标志物包括纹状体多巴胺能成像、代谢成像、黑质自由水/神经黑色素敏感/铁敏感成像及T1加权结构磁共振成像。
- 区分非典型帕金森综合征的疾病状态标志物包括代谢成像、自由水成像和T1加权成像。
- 早期帕金森病进展可用纹状体多巴胺能成像、代谢成像及后部黑质自由水和神经黑色素敏感成像监测。
- 中晚期帕金森病进展可用前部黑质自由水成像、黑质R2*和代谢成像监测,皮质厚度和脑回指数也可能是有用的进展标志物或预测因子。
- 多巴胺能成像和自由水成像可检测1年进展,其他模态检测进展需18个月或更长。
关键数值与推荐
- 进展生物标志物的可靠性随疾病阶段变化,而疾病状态标志物在临床前、前驱期、早期和中晚期个体中相对一致。
临床怎么用
- 在临床试验中可根据疾病阶段选择相应的影像生物标志物作为结局指标。
- 临床管理中可将影像生物标志物与常规临床评估多模态结合使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Imaging biomarkers in Parkinson disease (PD) are increasingly important for monitoring progression in clinical trials and also have the potential to improve clinical care and management. This Review addresses a critical need to make clear the temporal relevance for diagnostic and progression imaging biomarkers to be used by clinicians and researchers over the clinical course of PD. Magnetic resonance imaging (diffusion imaging, neuromelanin-sensitive imaging, iron-sensitive imaging, T1-weighted imaging), positron emission tomography/single-photon emission computed tomography dopaminergic, serotonergic, and cholinergic imaging as well as metabolic and cerebral blood flow network neuroimaging biomarkers in the preclinical, prodromal, early, and moderate to late stages are characterized. OBSERVATIONS: If a clinical trial is being carried out in the preclinical and prodromal stages, potentially useful disease-state biomarkers include dopaminergic imaging of the striatum; metabolic imaging; free-water, neuromelanin-sensitive, and iron-sensitive imaging in the substantia nigra; and T1-weighted structural magnetic resonance imaging. Disease-state biomarkers that can distinguish atypical parkinsonisms are metabolic imaging, free-water imaging, and T1-weighted imaging; dopaminergic imaging and other molecular imaging track progression in prodromal patients, whereas other established progression biomarkers need to be evaluated in prodromal cohorts. Progression in early-stage PD can be monitored using dopaminergic imaging in the striatum, metabolic imaging, and free-water and neuromelanin-sensitive imaging in the posterior substantia nigra. Progression in patients with moderate to late-stage PD can be monitored using free-water imaging in the anterior substantia nigra, R2* of substantia nigra, and metabolic imaging. Cortical thickness and gyrification might also be useful markers or predictors of progression. Dopaminergic imaging and free-water imaging detect progression over 1 year, whereas other modalities detect progression over 18 months or longer. The reliability of progression biomarkers varies with disease stage, whereas disease-state biomarkers are relatively consistent in individuals with preclinical, prodromal, early, and moderate to late-stage PD. CONCLUSIONS AND RELEVANCE: Imaging biomarkers for various stages of PD are readily available to be used as outcome measures in clinical trials and are potentially useful in multimodal combination with routine clinical assessment. This Review provides a critically important template for considering disease stage when implementing diagnostic and progression biomarkers in both clinical trials and clinical care settings.
引用
- Mitchell T, Lehéricy S, Chiu SY, et al. Emerging Neuroimaging Biomarkers Across Disease Stage in Parkinson Disease: A Review. JAMA Neurol. 2021. PMID: 34459865. doi:10.1001/jamaneurol.2021.1312
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。